Rap, a member of the Ras-like small G-protein family, is a key node among G-protein coupled receptors (GPCR), receptor tyrosine kinases (RTKs), ion channels and many other downstream pathways. Rap plays a unique role in cell morphogenesis, adhesion, migration, exocytosis, proliferation, apoptosis and carcinogenesis. The complexity and diversity of Rap functions are tightly regulated by Rap-interacting proteins such as GEFs, GAPs, Rap effectors and scaffold proteins. These interacting proteins decide the subcellular localization of Rap, the interaction modes with downstream Rap effectors and tune Rap as an atypical molecular conductor, coupling extra-and intracellular signals to various pathways. In this review, we summarize four groups of Rap-interacting proteins, highlight their distinctions in Rap-binding properties and interactive modes and discuss their contribution to the spatiotemporal regulation of Rap as well as the implications of targeting Rap-interacting proteins in human cancer therapy.
Introduction
Rap is a member of the Ras family of small G proteins and plays a central role in cell biology by coupling signals generated within biological membranes to intracellular effectors. Rap was first discovered as a Ras antagonist [1] , but further research found that in addition to its inhibitory and synergistic effect on Ras signalling, Rap functions in multiple key signalling pathways involving the regulation of integrin-mediated cell adhesion [2] [3] [4] , cellcell junction formation [5] [6] [7] , establishment of cell polarity [4, 8] , exocytosis [9, 10] , cell apoptosis [11, 12] , carcinogenesis [13] [14] [15] and cell proliferation [16, 17] . Mammalian cells express two Rap1 isoforms (Rap1A and Rap1B) and three Rap2 isoforms (Rap2A, Rap2B and Rap2C), whereas in yeast, there is only one Rap ortholog. Rap1 and Rap2 proteins share 60% sequence homology and signal through distinct downstream pathways [18] . Like other small G-proteins, Rap functions as a simple molecular switch with an inactive GDP-bound and an active GTP-bound conformation. However, this switch mechanism is regulated by Fig. 1 . A typical model of the activation and inactivation of Rap signalling. Rap signaling is controlled by extracellular and intracellular cues that impinge on the RapGEFs and RapGAPs, thereby determining when and where Rap is in the GTP-bound active state. Upstream signals can be transduced via G-protein coupled receptors (GPCR), receptor tyrosine kinases (RTKs) and ion channels, the post-translational modifications of the GEFs and GAPs, or through their interaction with proteins or lipids. These either affect the activity of RapGEFs and RapGAPs, mediate their local recruitment to specific cellular compartments, sequester them from signalling to Rap, or modulate their stability. Rap signaling is further controlled by pathways that regulate Rap independently of its nucleotide binding. In the GTP-bound conformation, Rap can interact with diverse effector proteins, such as B-Raf, C-Raf, AF-6, RAPL et al, to trigger downstream events. In addition, Rap-GTP interacts with PDZ-GEFs or PLCε to provide positive feedback to the local activation of Rap.
Fig. 2.
The domain structures of typical GEFs, GAPs and effectors of Rap. Most GEFs are identical for their CDC25HD domains and RA domains, among Rap-GEFs, DOCK4 is a atypical one, it does not contain the CDC25-HD; instead, a DOCK domain located at the C-terminal may conduct the Rap binding function. GAPs are identical for their GAP domains. Binding of GEFs with modulates the nucleotide-binding site of Rap, resulting in the release and subsequent replacement of the bound nucleotide by the cellularly abundant GTP. Explanation for abbreviations of important domains in this figure: CDC25-HD, CDC25 homology domain; RA, Ras/Rap association; BTK, Bruton's tyrosine kinase motif; CNB, cyclic nucleotide binding; CNB-L, cyclic nucleotide binding-like; DEP, dishevelled; Egl-10, pleckstrin; EF, EF-hands; GAP, GTPase-activating protein; PH, pleckstrin homology; PLC, phospholipase C catalytic domain; REM, Ras exchange motif; PDZ, PSD95, DlgA, Zo-1.
of cell adhesion and cell-cell junction formation [36, 37] . A cAMP analogue that specifically activates Epac can induce Rap-dependent cell adhesion. Indeed, Epac-Rap signalling has been shown to reduce vascular permeability by altering microtubule dynamics as well as enhancing junction molecules such as vascular-endothelial cadherin at cell-cell contacts [37] [38] [39] [40] [41] . Epac activation induces reorganization of cortical actin, which supports junctional adhesion molecules and thereby contributes to stabilizing endothelial barrier function. Chotani and his co-researchers proved that serum can induce cAMP-Rap pathway conducted alpha(2)-adrenoceptors expression in vascular smooth muscle cells [42, 43] . Epac signaling also contributes to axon specification, elongation and neuronal polarity [44] . These result indicated the significance of Epac-Rap signalling in cardiovascular and neuronal system. The effect of Epac on actin remodelling involves the activation of Rap1, which can then indirectly modulate the activity of the Rho GTPase family such as Rho and Rac through the recruitment of specific GEFs of the Rho family [45, 46] . cAMP analogues that specifically target the C-terminal helix of the cAMP-binding domain of Epac can inhibit or stimulate Epac activity and therefore attenuate or enhance Rap-conducted signalling. For example, the modified cAMP analogue N 6 -phenyl-cAMP can inhibit cAMP-induced Epac activation. Whereas another cAMP analogue 8-pCPT-2'-O-Me-cAMP, can activate Epac at a concentration much lower than that of cAMP itself [47] , in the following years this compound were developed more efficiently [48, 49] . Brown and his co-workers identified a thiobarbituric acid derivative, 5376753 [50] , that allosterically inhibits Epac activity and therefore modulates the activity of Rap and influences cell adhesion. Cell adhesion and conjunction are essential for tumour cell proliferation and migration and medical compounds based on cAMP analogue may suppress tumour progress via Epac/Rap pathway. Epac-dependent Rap activation may control neuronal excitability [51] . In this case, with cAMP analogs, researchers induces a potent activation of the Ca 2+ -sensitive big K + channel, slight membrane hyperpolarization, and increased after-hyperpolarization in cultured cerebellar granule cells, and observing activation of both Rap and p38 MAPK, which mobilizes intracellular Ca 2+ stores.
CalDAG-GEF
Epac proteins are not the only members of the Rap-GEF family regulated by second messengers; Rap activation by CalDAD-GEF1 and CalDAG-GEF2 rely on the release of Ca 2+ and diacylglycerol (DAG) [52] . CalDAG-GEF are also referred to as Rasguanyl nucleotide releasing proteins (RasGRPs) and have a catalytic region composed of a Ras exchange motif (REM) and a CDC25 domain. However, CalDAG-GEFs lack the cyclic nucleotide-binding domains, have a [53] (Fig. 2) . DAG directly activates CalDAG-GEFs by a membrane recruitment mechanism as well as indirectly by PKCmediated phosphorylation (Fig. 3) [26] . CalDAG-GEFs are prominently expressed in blood cells. CalDAG-GEF2, through Rap, plays a role in controlling platelet adhesion, whereas RasGRP4 controls Ras activation in mast cells [54] . A malfunctioning CalDAG-GEFs likely contributes to autoimmunity and blood malignancies and may prove to be viable drug targets for these conditions. Calphostin C is thought to block C1 domain function and has been used to inhibit both PKC and RasGRPs [24] . DAG analogues such as bryostatin-1, can act as a RasGRP-activating compound [55] and considerable success has been achieved in designing other DAG analogues with selectivity for RasGRP versus PKC C1 domains.
PDZ-GEF
PDZ-GEF is another Rap activator. Even though PDZ-GEF proteins contain regions homologous to cyclic nucleotide-binding domains and have an auto-inhibitory function similar to Epac, their activation is not regulated by cAMP [35] . Interestingly, PDZ-GEF has a Ras/Rap-association domain (RA) close to the CDC25 homology domain that is commonly observed in downstream Rap effectors [56] (Fig. 2) , suggesting that PDZ-GEF serves not only as a Rap activator but also as a positive feedback control factor [57] (Fig. 1) . The PDZ-GEF family has two members, PDZ-GEF1 and PDZ-GEF2, which localize to cell-cell junctions via β-catenin and MAGI proteins, the latter being required for activation of Rap1 at cell-cell contacts and adhesions [58, 59] . In epithelial cells, PDZ-GEF1 is rapidly phosphorylated by I-kappa-B-kinase-β and casein kinase-1α and consequently degraded by the proteasome via the SCF (βTrCP) ubiquitin ligase [60] . Failure to degrade PDZ-GEF1 in epithelial cells results in sustained activity of Rap1 and inhibition of cell migration induced by HGF, a potent metastatic factor. Furthermore, expression of a degradation-resistant PDZ-GEF1 mutant greatly suppresses dissemination and metastasis of human breast cancer cells [60] . The interaction of PDZ-GEF1 with an internalized neurotrophin receptor transported to late endosomes induces sustained activation of both Rap1 and ERK [61] , suggesting that PDZGEFs regulate Rap1 activation and its feedback signalling is important for neurite outgrowth. Not only in cancer and neural cell growth, the important role of PDZ-GEFs and Rap1 in vessel angiogenesis has also been demonstrated by a recent report [62] , in which researchers showed that Polo-like kinase 2 (PLK2) regulates Rap1 activity to guide endothelial tip cell lamellipodia formation and subsequent angiogenic sprouting. These findings indicate that PDZ-GEFs's role as both Rap activators and effectors may be a universal mechanism existing in various tissues and cell types.
C3G (Rap-GEF1)
C3G was identified as a Crk SH3-binding guanine nucleotide exchange factor [63] . As a GEF, C3G not only act on Ras family GTPases Rap1, Rap2, TC21 and R-Ras, but also on Rho family member TC10 [64] . It can associate with the cytoskeleton and stabilizes microtubules but overexpression of C3G can reverse EGF-induced cell morphological transformations [65] . C3G expression is also associated with a decrease in cellular β-catenin levels, which can induce neurite-like extensions (NLE) in MDA-MB-231 and BT549 breast carcinoma cells and inhibit their motility [66] . In this process, C3G may act by destabilizing β-catenin protein and inhibiting its nuclear accumulation and independent of its role as a RapGEF [67] . Unlike Epac, C3G lacks the cAMP-binding domain but has a proline-rich sequence in the central region that enables it to interact with SH3-containing proteins such as Crk, Hck, c-Abl and Cas [63, 68] . C3G also has an E-cadherin interacting domain in the N-terminus. For this reason, C3G-conducted Rap activation involves cadherin induced cell-cell junction formation and receptor tyrosine kinase (RTK)-initiated, Crk-mediated, cell adhesion ( Fig. 3) [64, 68] . C3G-dependent activation of Rap1 is essential for adhesion and spreading of embryonic fibroblasts. C3G-knockout mice died in the early embryonic stage, transgenic expressing human C3G gene in C3G -/-MEF cells could restore the cell adhesion ability therefore rescued mouse embryo from C3G deficiency [69] . The effects of C3G over-activity can be suppressed by reducing the gene dose of components of the Ras-MAPK and Rap1 pathways. C3G is likely to stimulate both Ras1 and Rap1 directly, which in turn leads to a convergent activation of the MAPK pathway [70] . C3G can act as an inhibitory factor of p38 MAPK via a Rap1-dependent manner and remarkably reversed the apoptosis mediated by p38 in chronic myeloid leukemia (CML) cells [71] , interestingly, in the same works, researchers also showed C3G's pro-apoptotic functions by inhibiting Erk and Akt activation via a Rap-independent manner. The dual regulatory role of C3G was confirmed by other researchers, they also pointed that C3G's action (pro-or anti-apoptic) mainly depends on the sort of stimuli upon cells [11] . In response to mechanical signals such as cytoskeletal stretch, C3G was found to associate with Triton-insoluble structures to locally activate Rap1. C3G is phosphorylated in response to adhesion to fibronectin and overexpression in Ba/F3 haematopoietic cells enhances migration. Drugs targeting C3G may restrict Rap activities that promote tumour progress. In some early works by Guerrero et al, C3G was also indicated as a tumour suppressor and not involved with Rap activation [72, 73] . The dual apoptosis-regulatory role of C3G and its involvement in multiple pathways make anti-tumuor strategy targeting C3G a quite tough work.
DOCK4
As a member of the dedicator of cytokinesis (DOCK) family, DOCK4 is an atypical Rap-GEF and was identified in a screen for tumour suppressor genes in mice. DOCK4 functions as a GEF and is involved in regulation of adherens junctions between cells. Mutations in this gene have been associated with ovarian, prostate, glioma, and colorectal cancers [74, 75] . Unlike other types of Rap-GEFs, DOCK4 does not contain the CDC25-HD; instead, a DOCK domain located at the C-terminal may conduct the Rap binding function [76] . DOCK4 has GEF activity for both Rap and Rac [77, 78] . Osteosarcoma cells lacking DOCK4 do not form intercellular junctions but are rescued by expression of an active Rap1 mutant, indicating a role for DOCK4 as a Rap-GEF in junction formation. DOCK4 mutations are present in a subset of human cancer cell lines, resulting in the disruption of Rap regulated intercellular junctions during tumourigenesis [74, 79] . The engulfment defect of C. elegans mutants lacking the CDM gene ced-5 is rescued by wild-type DOCK4 but not by the mutant allele. Expression of wild-type but not mutant DOCK4 in mouse osteosarcoma cells with a deletion of the endogenous gene suppresses growth on soft agar and tumour invasion in vivo [74] . These findings indicate that DOCK4-induced Rap activation and its consequent effects on cell junction formation is essential for tumour growth and argues for the development of DOCK 4 mutation specific targeted therapies. 
Rap1GAP
Rap1GAP include two members, Rap1GAP1 and Rap1GAP2. In addition to the GAP domain, they both have a GoLoco region, which conducts the binding to Gα proteins [83] . Rap1GAP1b, an isoform of Rap1GAP1 with an N-terminal extension, interacts with activated Gα i [84] , whereas Rap1GAP1a binds to active Gα z [85] . Phosphorylation of Rap1GAP2 upon platelet activation leads to its sequestration by the scaffolding protein 14-3-3, contributing to platelet adhesion and aggregation [86, 87] . Endothelium-derived signals that inhibit platelet aggregation release 14-3-3 by PKA and PKG-mediated phosphorylation of Rap1GAP2 on a residue adjacent to the 14-3-3 binding site [87] . Rap1GAP is highly expressed in normal human thyroid cells and decreased in five papillary thyroid carcinomas [88] . Rap1GAP is a critical regulator of aggressive tumour cell behaviour and the level of Rap1GAP expression influences tumour cells migratory mechanisms. Human colon cancer cells depleted of Rap1GAP are endowed with more aggressive migratory and invasive properties [89] . Overexpression of Rap1GAP in human colon cancer cells impairs Rap2 activity and the ability of cells to spread and migrate on collagen IV [90] . These results indicate that the inhibitory effects of Rap1GAP on Rap are essential for tumour suppression.
Spa-1 and SPAR
Spa-1 and SPAR both have PDZ domains and regulate Rap activity by mediating different protein complex formations and therefore influence various biological processes. Many scaffold proteins, including Spa-1 and SPAR contain at least one domain in common, the PDZ domain, which binds the carboxyl terminus of a variety of proteins, including those of transmembrane receptors and other PDZ domains [91] . The Rap-effector AF-6 can simultaneously bind RapGTP and Rap1GAP or Spa-1 to recruit GAP activity to Rap within the same molecular complex, the binding of AF-6 with Spa-1 takes place at PDZ domain, which is also contained by AF-6 [92] . Spa-1 plays an important role in controlling metastatic efficiency of human prostate cancer by regulating the expression of and interaction with ECM at the primary site [93] . Inactivation of Spa-1 results in Rap1 hyper-activation in haematopoietic cells and over time leads to features associated with symptoms typical of human myeloid dysplastic and myeloid proliferative diseases [94] . Spa-1 regulated Rap signalling plays a pivotal role in leukaemia genesis and cancer metastasis [95] .
The SPAR protein family consists of three members (SPAR1-3). Unlike Spa-1, SPARconducted Rap inactivation mainly affects neuronal activities [96] . SPAR and SNK (seruminducible kinase) signalling pathways may be involved in the damage to hippocampal neuronal dendritic spines following glutamate-induced excitotoxicity [97] . During the homeostatic response to chronic elevated activity, NF-κB activation by SNKs opposes SNK-mediated SPAR degradation by transcriptionally up-regulating SPAR in mouse hippocampal neurons in vitro and in vivo. Exogenous SPAR expression can rescue the overshooting of homeostatic reductions at excitatory synapses in NF-κB-deficient neurons responding to elevated activity [98] . Non-canonical Wnt signalling elevates RapGTP due to degradation of SPAR induced by casein kinase I-mediated phosphorylation, an essential process for gastrulation during both Xenopus and zebrafish development [99] . The maturation of dendritic spines requires fine-tuning of Rap1 activity, mediated by targeting of SPAR1 to the post-synaptic density by a diverse array of scaffold proteins [100] . Polo-like kinase 2 (Plk2) directs elimination of SPAR via phosphorylation-dependent ubiquitin-proteasome degradation. Conversely, Plk2 phosphorylation stimulates Rap activator PDZ-GEF1 [101] , indicating that SPAR/Rap signalling plays a vital role in homeostatic plasticity.
Effectors
In addition to C-Raf and B-Raf, a large number of proteins have been identified as effectors of Rap proteins including the adapters RapL, Riam, AF-6, and Krit1; the RacGEFs Tiam1 and Vav2; and the RhoGAPs RA-RhoGAP, RGS14 and Arap3 (Fig. 2) .
C-Raf
The C-Raf (Raf-1) serine/threonine kinase is a key effector of Ras-mediated signal transduction. In response to a diverse array of extracellular signals, activated Ras interacts directly with C-Raf and recruits it from the cytosol to the plasma membrane. At the membrane, C-Raf becomes activated and phosphorylates MEK1 at serine residues 217 and 221. These phosphorylation events result in the activation of MEK1, which in turn phosphorylates and activates MAPK (ERK1 and ERK2) [102] [103] [104] [105] . An aspect of Rap that has attracted researchers attention is its ability to bind C-Raf [1, 106] . The translocation of C-Raf to the plasma membrane is inhibited after interacting with Rap and thus C-Raf mediated ERK activation is attenuated [107] . In human peripheral blood mononuclear cells, prostacyclin analogue treprostinil can activated Rap and limits ERK activity, which results in impaired adhesion of fibrocytes [108] . However, in vascular smooth muscle cells (VSMCs), Rap2 can induce C-Raf up-regulation and acts downstream of the fibroblast growth factor receptor 1 (FGFR1) to stimulate cell migration [109] . These results indicate that the regulation of C-Raf by Rap is essential for the increase of cell mobility and this process is associated with ERK inactivation.
B-Raf
Mutated B-Raf-mediated constitutive activation of ERK1/2 is involved in approximately 66% of all cutaneous melanomas. The effect of Rap on B-Raf is opposite to that of C-Raf, early studies showed that Rap can activate the B-Raf mediated MAPK cascade [110] . Further research then indicated the activation of PDZ-GEF2 can stimulate Rap1 and lead to an increase in B-Raf, MEK, and ERK activity [111] . PKA-independent, cAMP-dependent Rap activation leads to subsequent activation of B-Raf/ERK and mTOR signalling in human cancer cells [112, 113] . Activation of Rap1 is involved in the RET/PTC (papillary thyroid carcinoma)-mediated stimulation of B-RAF kinase and the ERK1/2. Rap1 is a downstream effector of RET/PTC and may contribute to the transformed phenotype of RET/PTCexpressing thyrocytes [114] . The B-Raf mutation V600E results in elevated kinase activity and is commonly found in malignant melanoma, and similarly, the activation effects of Rap on the B-Raf/MEK ERK pathway contribute to cancer development.
Arap3
Arap3 was first identified as a Rho GAP [115] and further studies showed that it can act as a point of convergence for Arf and Rho signalling [116, 117] . When associated with PtdIns (3,4,5) P3, a product of PI3K, Arap3 can translocate to the plasma membrane where it binds Rap directly with its C-terminal RBD domain. The Rho and Arf family small of GTPases are well-known regulators of cellular actin dynamics [118] . In response to nerve growth factor (NGF) or basic fibroblast growth factor (bFGF), Rap1 can upregulate Arap3 leading to RhoA inactivation and neurite outgrowth in Rat pheochromocytoma (PC12) cells [116, 117] . These findings indicate that as a Rap-effector, Arap3 plays an important role in mediating PI3K-dependent crosstalk between the Ras, Rho, and Arf family small of GTPases.
AF-6/Afadin
AF-6 is a Rap-regulated actin-binding protein that promotes cadherin complex assembly as well as the binding of many other cell adhesion molecules and receptors [119, 120] . Interestingly, AF-6 has a PDZ domain consensus with that in Rap-GEFs, this domain can bind the COOH-terminal of nectin, an immunoglobulin-like cell adhesion molecule [121] , thus AF-6 plays important cooperative roles in the formation of adherens junctions, and is associated with the actin cytoskeleton [121, 122] . With its N-terminal RA domain, AF-6 binds both Ras and Rap1 with high affinity. Although initial studies showed that AF-6 might participate in Ras-induced junction breakdown [123] , other research showed that AF-6 binds p120 catenin in a Rap-dependent manner to prevent internalization of E-cadherin [124] . However, a longer isoform of AF-6 that regulates E-cadherin in a Rap-independent manner has recently described [120] . Thus, a clear picture of the role of AF-6 as an effector of Ras and/or Rap in junctions has not been made. In T-cells, AF-6 is a negative regulator of Rap-induced integrin-mediated cell adhesion [125] . Rap mediated AF-6 activation is crucial for cadherin recruitment and is necessary for spine and synapse formation in vivo.
Krit1
Krit1 (Krev Interaction Trapped 1) is a Rap1-interacting protein that was originally identified in a yeast two-hybrid screen [126, 127] . This protein, also called CCM1, is mutated in cerebral cavernous malformation, a disease associated with defects in brain vasculature [128] [129] [130] . Krit1 has several ankyrin repeats and a FERM domain [131] . The FERM domain has an ubiquitin-like fold that is similar to RA and RBD domains and can bind both Ras and Rap, although its affinity for Rap is higher than for Ras [132] . Recent evidence implicates Krit1 as a major effector of Rap1 in the control of endothelial cell-cell junctions [133, 134] . In endothelial cells, Krit1 localizes to the junctions where it associates with junctional proteins and is required for the Rap1-induced reduction in basal and cytokine-induced permeability of the junctions [135] . Krit1 also associates with microtubules [136] , two other CCM proteins (CCM2 and CCM3), and ICAP1 (a protein that binds to and negatively regulates the β1 chain of integrins) [137] . Rap1 can release Krit1 from microtubules by binding to its FERM domain [137, 138] . By interacting with heart-of-glass receptor and β-catenin, Rap1 also enhances KRIT1 localization to cell-cell contacts [138, 139] . KRIT1's interaction with ICAP1 releases ICAP1 from integrin β tails, potentially facilitating nuclear translocation of ICAP1 [138, 140] .
Riam
Riam (Rap1-GTP-interacting adaptor molecule) is a molecular partner of active Rap1 first characterized as a VASP-binding protein that functions downstream of Rap1 in T lymphocytes [141] . Riam contains an N-terminal coiled-coil region, a central RA and PH domain, and a proline-rich C-terminal region, with multiple FPPPP motifs capable of interacting with the EVH1 domains of the actin regulatory proteins Ena and Vasp. Riam interacts with active Rap1 to stimulate the adhesion of Jurkat T-cells through β1 and β2 integrins [142] . Ginsberg and co-workers [143] showed that Riam is involved in stimulus-induced, Rap1-mediated recruitment of talin. Talin subsequently binds to and activates the β chain of integrin αIIbβ3. In T-cells, Riam was found in a complex with ADAP (adhesion-and degranulation-promoting adapter protein) and SKAP-55 (Src kinase-associated phosphoprotein of 55 kDa), and this complex is required for Rap1 recruitment to the plasma membrane and T-cell receptorinduced, integrin-mediated cell adhesion to fibronectin and ICAM (intercellular adhesion molecule) [141] . Riam is sufficient for preventing integrin α4 activation by chemoattractants or activated PI3Kγ, whereas activated Rap promotes constitutive integrin activation and cell adhesion that can be blocked only by inhibition of Riam or integrin α4β1. Similar to blockade of PI3Kγ or integrin α4β1, blockade of Rap1A suppresses recruitment of monocytes and granulocytes to tumours and tumour progression [144] . Riam is also highly involved in HPK1-associated, Rap1-mediated B-lymphocyte adhesion [145] . Riam depletion reduces β1 integrin-dependent melanoma cell adhesion, which correlates with decreased activation of both ERK1/2 MAPK and phosphatidylinositol 3-kinase, two central molecules that control cell growth and survival. In addition to causing inhibition of cell proliferation, RIAM silencing leads to higher susceptibility to cell apoptosis [146] . Together, these data suggest that defective activation of these kinases in Riam-silenced cells could account for inhibition of melanoma cell growth and that RIAM may contribute to the dissemination of melanoma cells.
RapL
RapL (regulator of adhesion and cell polarity enriched in lymphoid tissues/Nore1B/ Rassf5) is another regulator of Rap-induced, integrin-mediated adhesion in T-cells. In vivo, RapL binds Rap1 after stimulation by the T-cell receptor or by chemokines. In the presence of active Rap1, RapL binds to the α chain of integrin αLβ2 (LFA-1) resulting in its activation [2] . Data from RapL knock-out mice confirm its role in lymphocyte adhesion. Lymphocytes lacking RapL are less adherent to ICAM and do not redistribute their integrins after cytokine stimulation and are defective in cell migration and thus in homing to peripheral lymph nodes [147] . Recently, the kinase Mst1 was identified as an effector of RapL in T-cell adhesion. Activation of Rap1 promotes the binding of RapL to Mst1 and their re-localization with LFA-1 to the leading edge to induce adhesion [4] . Interestingly, where Rap1 and RapL have been shown to regulate both LFA-1 affinity and clustering, Mst1 overexpression enhances only LFA-1 clustering. This suggests that LFA-1 clustering is critical for Rap1-induced T-cell adhesion and that there may also be Mst1-independent mechanisms by which Rap1 regulates LFA-1 affinity. Moreover, in a different T-cell line, RapL was found to interact with Rap2B and regulate random migration but not cell adhesion [148] . RapL is also known as a tumour suppressor and transient expression of RapL results in enhanced apoptosis and delayed cell cycle progression. RapL is strongly suppressed in neuroblastic tumours and reconstitution of its expression diminishes the tumourigenic phenotype [149] . These findings indicate that Rap activation may suppress tumour progress via RapL.
PLC
Phosphoinositide-specific phospholipase C (PLC) hydrolyses PIP2 to produce inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which can in turn activate downstream targets important for cell proliferation and differentiation, such as protein kinase C (PKC) and Calcium-dependent signalling pathways [150, 151] . There are 13 mammalian PLC isozymes that have been documented and divided into six subfamilies [152] . PLC family members can act as Rap effectors or Rap-GEFs; PLCε also contains a CDC25 homology domain, which enhances guanine nucleotide exchange on Rap1 [108] . PLCε interacts with Rap1 and Rap2 via a C-terminal RA domain and provides positive feedback during cAMP-Epac1-mediated Rap activation [153] (Fig. 1) . PLCε plays a crucial role in cardiac semilunar valvulogenesis downstream of the EGF receptor, as well as in chemical carcinogen-induced skin tumour development downstream of Ha-Ras. Stimulation of cultured mammalian cells with growth factors induces translocation of PLCε from the cytoplasm to the plasma membrane and to the Golgi apparatus through direct association at its RA domains with the GTP-bound forms of Ras and Rap1 [154] . PLCε phosphatidylinositol 4,5-bisphosphate hydrolytic activity and PLCε-stimulated Rap1 GEF activity are both required for PLCε-mediated enhancement of sarcoplasmic reticulum Ca 2+ release and that PLCε significantly enhances Rap activation in response to beta-adrenergic receptor stimulation in the heart [155] . PI3Kγ-activated PLCγ can lead to RasGrp/CalDAG-GEF-I and II mediated, Rap1A-dependent activation of integrin α4β1, extravasation of monocytes and granulocytes, and inflammation-associated tumour progression.
Co-regulators for Rap
Although the various GEFs and GAPs play decisive roles in determining the activation state of Rap, the activation process also requires adaptors to help with recruiting Rap to the appropriate location and to activate or inactivate it at the appropriate time. The coregulators for Rap can be classified into two groups regulating the activities or functions of GRFs or GAPs.
Proteins regulating GEFs
The proteins regulating Rap-GEFs include two sub-groups, protein kinases and junctional proteins. Protein kinases phosphorylate certain sites on the GEFs and junctional proteins usually serve as scaffold proteins.
Protein kinases: One of the main regulating groups of Rap-GEFs are the protein kinase. PKCθ phosphorylates CalDAG-GEF3 on Thr133 and PKC phosphorylates CalDAG-GEF1 on the homologous residue, Thr184. CalDAG-GEF phosphorylation by PKC is a mechanism that integrates DAG signalling systems in T and B cells. PKC-mediated regulation of CalDAGGEFs in lymphocytes may generate cooperative signalling in response to increases in DAG [156] . Multiple PKC isoforms phosphorylate CalDAG-GEF3 adjacent to its CDC25-HD, which promotes catalytic activity without affecting membrane recruitment [25, [157] [158] [159] . The tyrosine kinases Src can phosphorylate C3G with the help of the adapter protein Crk, which is phosphorylated by receptor tyrosine kinases (RTKs) and located to cell membrance [69, [160] [161] [162] and another tyrosine kinase c-Abl can also phosphorylate C3G with the help of F-actin, and furtherly induce cell death [163] . In addition to targeting C3G to its substrate Rap, membrane recruitment by Crk might indirectly control the nucleotide exchange activity of C3G by allowing its phosphorylation [164] . The phosphorylation effects of Rap-GEFs are essential for the transformation of Rap from an inactive to an active state.
Junctional proteins: Cadherin, Nectin and JAM-A are key components in Rap-mediated cell-cell junction formation. Rap-GEFs either directly or indirectly interact with different junctional components. PDZ-GEF2 interacts through its PDZ-domain with the C-terminus of the tight junction protein JAM-A [165, 166] . Nectins associate with C3G and mediate its recruitment to the junctional complex [167] . The C-terminus of E-cadherins directly binds C3G and, furthermore, interacts with PDZ-GEF1 through β-catenin and MAGI-1 [7, 168, 169] . An interaction between Epac1 and E-cadherins via the phosphodiesterase PDE4D has also been demonstrated [170] . These types of scaffold proteins help GEF and Rap locate to the appropriate sub-cellular position and accomplish Rap's function.
Proteins regulating GAPs
The interaction of GAPs with their co-regulators further defines the localization and duration of Rap signalling and even reverses the dynamic processes controlled by Rap. Rap-GAPs are targeted to different molecular complexes at various cellular locations. Local signalling of Rap1GAP1 at the plasma membrane is established by binding to Gα proteins, which are activated by the associated G-protein coupled receptors. Rap1GAP1b, an isoform of Rap1GAP1 with an N-terminal extension, interacts with activated Gα i [84] , whereas Rap1GAP1a binds to active Gα z [85] . Consequently, receptor-mediated activation of these Gα proteins reduces membrane-localized Rap1GTP levels [84, 171] . The cytosolic tail of Ephrin receptors interacts with the PDZ-domain of SPAR, which couples Ephrin signalling to growth cone collapse in hippocampal neurons [172] . Rap1GAP2 is associated with signal scaffolding protein 14-3-3, as we have previously discussed.
Concluding remarks
Rap is a unique member of the Ras G protein family, but it does not simply act as a suppressor of Ras-dependent transformation. Recent studies have revealed that Rap is a pivotal conductor manipulating a large group of proteins that form an orchestra that controls plenty of biological processes including cell proliferation, secretion, inflammation, differentiation, and migration ( Fig. 3 and 4) .
The activation and deactivation of Rap is tightly controlled by Rap-GEFs and GAPs. The diversity in structure and interacting mode of the GEFs and GAPs for Rap reveal a large variety of regulatory mechanisms that control their activity, cellular distribution, and stability. Together, these inputs define the activity of the Rap small G-proteins in time and space. This complex regulation of Rap enables the control of dynamic, local processes such as cell adhesion, cell migration and secretion. In mammalian cells, activation of the different cellular pools of Rap is established by multiple distinctively controlled GEFs. Feedback through the recruitment of various GEFs by active Rap can locally amplify this signal and prolongs the duration of Rap signalling [27, 61, 165] . For Rap-GAPs, accumulating data indicates that they function in the reversion of these dynamic processes and might prevent events occurring at the wrong location by locally restricting Rap activity. The presence of multiple Rap proteins, Rap-GEFs and Rap-GAPs in mammalian cells indicates that different Rap signalling modules can exist and function simultaneously to direct distinct local events. Each of these Rap modules might use different effector proteins, explaining the multitude of Rap effectors currently implicated in Rap-regulated processes. For instance, Epac1-induced Rap activation requires the assistance of anchor protein ERM (ezrin-radixin-moesin) and translocation of Epac1 to the plasma membrane [173, 174] . The distinct local events could impinge on the same biological response, however, as illustrated by the regulation of cellcell junctions involving multiple Rap-GEFs. The diversity of protein interaction network with Rap in the center makes Rap's biological functions complicated (Fig. 4) . Like a director of a symphony orchestra, Rap controls many players, but the final effects that change cell behaviors depends not only on Rap alone, but also on tacit degree of Rap and its activators, inhibitors, or effectors. Blocking the communication of Rap with its interaction proteome or targeting related scaffold proteins and co-effectors can dramatically change the functions of Rap signaling.
Furthermore, Rap dysregulation plays a vital role in a variety of cancers including thyroid [175] , colon [176] , melanoma [177] , prostate [178] , pancreatic [179] , and squamous cell carcinoma of the head and neck [179, 180] . Constantly activated GEFs or downregulated Rap-GAPs enable Rap to stay in an over-activated state. Termination of the Rap cycle results in the aberrant behaviours of tumour cells, which can then prevent tumour progression, the typical example of which is the suppressive effect of mutated Rap-GEF PDZ-GEF1 on breast cancer cells but the depletion of Rap1GAP endows tumour cells with more aggressive migratory and invasive properties as discussed above. These findings indicate that the activation and deactivation cycle of Rap is essential for the adhesion and migration behaviours of tumour cells. Targeting Rap and its regulators and effectors may provide more therapeutic methods for cancer treatment. 
